•
Mar 31, 2022

Bio-key Q1 2022 Earnings Report

BIO-key's Q1 revenue improved driven by increase in software license fees.

Key Takeaways

BIO-key's Q1 2022 revenue increased by 3% to $1.94 million compared to Q1 2021, driven by a 205% increase in software license fees. The company reported an operating loss of $1.0 million and a net loss of $1.0 million, or $0.12 per share.

Q1 2022 revenue increased 3% to $1.94M from $1.89M in Q1 2021.

Software license fees increased 205% year-over-year.

Gross profit grew to $1.6M in Q1 2022 from $1.1M in Q1 2021.

Company remains confident in achieving full-year 2022 revenue guidance of $10-13M.

Total Revenue
$1.94M
Previous year: $1.89M
+2.8%
EPS
-$2.16
Previous year: -$1.62
+33.3%
Gross Profit
$1.6M
Previous year: $1.1M
+45.5%
Cash and Equivalents
$5.8M
Previous year: $13.5M
-57.0%
Free Cash Flow
-$1.44M
Previous year: -$3.21M
-55.2%
Total Assets
$19.4M
Previous year: $17.8M
+9.0%

Bio-key

Bio-key

Bio-key Revenue by Segment

Forward Guidance

BIO-key anticipates continued growth in software license revenue, along with hardware and services revenue contributions, and remains confident in achieving its full-year 2022 revenue guidance of $10-13M.

Positive Outlook

  • Growing momentum in Annual Recurring Revenue (ARR) base from software licenses.
  • Expanding worldwide opportunity to grow software license revenue base.
  • Compelling security, scalability, ease of use and deployment, and customer value proposition of PortalGuard IAM platform.
  • Strong capital position.
  • Talented global management and product development teams.

Challenges Ahead

  • Episodic nature of hardware sales can create variability in quarterly operating performance.
  • Increase in research, development and engineering expense.
  • Increase in selling, general and administrative expense.
  • Operating loss of $1.0M in Q1 2022.
  • Net loss available to common stockholders of $1.0M.

Revenue & Expenses

Visualization of income flow from segment revenue to net income